BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 37916388)

  • 1. Unlocking the therapeutic potential of targeting
    Samiksha S; Chan LN
    Haematologica; 2024 May; 109(5):1317-1319. PubMed ID: 37916388
    [No Abstract]   [Full Text] [Related]  

  • 2. Charting a path through resistance: histone deacetylase inhibitors for
    Kugler E
    Haematologica; 2024 Jun; 109(6):1643-1645. PubMed ID: 38356461
    [No Abstract]   [Full Text] [Related]  

  • 3. Profiling the activity of the para-caspase MALT1 in B-cell acute lymphoblastic leukemia for potential targeted therapeutic application.
    Safa FM; Rasmussen T; Fontan L; Xia M; Melnick A; Wiestner A; Lobelle-Rich P; Burger JA; Mouawad Y; Safah H; Flemington EK; Saba NS
    Haematologica; 2024 May; 109(5):1348-1358. PubMed ID: 37767562
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MALT1 Inhibition as a Therapeutic Strategy in T-Cell Acute Lymphoblastic Leukemia by Blocking Notch1-Induced NF-κB Activation.
    Wang R; Zhang H; Xu J; Zhang N; Pan T; Zhong X; Zhang H; Yin L; Yao Y; Wu Q; Li Z; Liu X; Xu K; Niu M
    Front Oncol; 2020; 10():558339. PubMed ID: 33072583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of MALT1-A20-NF-κB in adult B-cell acute lymphoblastic leukemia.
    Xu Y; Hu J; Wang X; Xuan L; Lai J; Xu L; Chen S; Yang L; Luo G; Zhu K; Wu X; Li Y
    Cancer Cell Int; 2015; 15():73. PubMed ID: 26213496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of CARMA1-BCL10-MALT1-A20-NF-κB expression in T cell-acute lymphocytic leukemia.
    Ma Y; Liao Z; Xu Y; Zhong Z; Wang X; Zhang F; Chen S; Yang L; Luo G; Huang X; Huang S; Wu X; Li Y
    Eur J Med Res; 2014 Nov; 19(1):62. PubMed ID: 25384343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting MALT1 for the treatment of diffuse large B-cell lymphoma.
    Seshadri MR; Melnick AM
    Leuk Lymphoma; 2022 Apr; 63(4):789-798. PubMed ID: 34783281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CD123 expression patterns and selective targeting with a CD123-targeted antibody-drug conjugate (IMGN632) in acute lymphoblastic leukemia.
    Angelova E; Audette C; Kovtun Y; Daver N; Wang SA; Pierce S; Konoplev SN; Khogeer H; Jorgensen JL; Konopleva M; Zweidler-McKay PA; Medeiros LJ; Kantarjian HM; Jabbour EJ; Khoury JD
    Haematologica; 2019 Apr; 104(4):749-755. PubMed ID: 30361418
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anlotinib Inhibits Proliferation and Induces Apoptosis in B-cell Acute Lymphoblastic Leukemia by Targeting the BTK and AKT/mTOR Pathway.
    Shi X; Li S; Tang S; Lu Y
    Anticancer Agents Med Chem; 2023; 23(12):1397-1405. PubMed ID: 36856175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blood MALT1 deficiency is common and relates to unfavorable induction therapy response and survival profile in acute myeloid leukemia patients.
    Geng H; Wang Y; Wang S
    Hematology; 2022 Dec; 27(1):1176-1183. PubMed ID: 36314929
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting B-cell lymphomas with inhibitors of the MALT1 paracaspase.
    Hailfinger S; Lenz G; Thome M
    Curr Opin Chem Biol; 2014 Dec; 23():47-55. PubMed ID: 25285878
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advances in the molecular pathobiology of B-lymphoblastic leukemia.
    Zhou Y; You MJ; Young KH; Lin P; Lu G; Medeiros LJ; Bueso-Ramos CE
    Hum Pathol; 2012 Sep; 43(9):1347-62. PubMed ID: 22575265
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High CD45 surface expression determines relapse risk in children with precursor B-cell and T-cell acute lymphoblastic leukemia treated according to the ALL-BFM 2000 protocol.
    Cario G; Rhein P; Mitlöhner R; Zimmermann M; Bandapalli OR; Romey R; Moericke A; Ludwig WD; Ratei R; Muckenthaler MU; Kulozik AE; Schrappe M; Stanulla M; Karawajew L
    Haematologica; 2014 Jan; 99(1):103-10. PubMed ID: 23911702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tumor suppressors BTG1 and IKZF1 cooperate during mouse leukemia development and increase relapse risk in B-cell precursor acute lymphoblastic leukemia patients.
    Scheijen B; Boer JM; Marke R; Tijchon E; van Ingen Schenau D; Waanders E; van Emst L; van der Meer LT; Pieters R; Escherich G; Horstmann MA; Sonneveld E; Venn N; Sutton R; Dalla-Pozza L; Kuiper RP; Hoogerbrugge PM; den Boer ML; van Leeuwen FN
    Haematologica; 2017 Mar; 102(3):541-551. PubMed ID: 27979924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alteration of gene expression profile in CD3
    Wang X; Lu S; Xiao Y; Xu L; Zhou L; Hu J; Li B; Zeng C; Li Y
    Immunotargets Ther; 2018; 7():77-81. PubMed ID: 30538965
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunophenotypic challenges in diagnosis of CD79a negativity in a patient with B acute lymphoblastic leukemia harboring intrachromosomal amplification of chromosome 21: a case report.
    Berhili A; Bensalah M; ElMalki J; Elyagoubi A; Seddik R
    J Med Case Rep; 2021 Oct; 15(1):531. PubMed ID: 34706776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognosis of children with mixed phenotype acute leukemia treated on the basis of consistent immunophenotypic criteria.
    Mejstrikova E; Volejnikova J; Fronkova E; Zdrahalova K; Kalina T; Sterba J; Jabali Y; Mihal V; Blazek B; Cerna Z; Prochazkova D; Hak J; Zemanova Z; Jarosova M; Oltova A; Sedlacek P; Schwarz J; Zuna J; Trka J; Stary J; Hrusak O
    Haematologica; 2010 Jun; 95(6):928-35. PubMed ID: 20145275
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B-cell receptor-driven MALT1 activity regulates MYC signaling in mantle cell lymphoma.
    Dai B; Grau M; Juilland M; Klener P; Höring E; Molinsky J; Schimmack G; Aukema SM; Hoster E; Vogt N; Staiger AM; Erdmann T; Xu W; Erdmann K; Dzyuba N; Madle H; Berdel WE; Trneny M; Dreyling M; Jöhrens K; Lenz P; Rosenwald A; Siebert R; Tzankov A; Klapper W; Anagnostopoulos I; Krappmann D; Ott G; Thome M; Lenz G
    Blood; 2017 Jan; 129(3):333-346. PubMed ID: 27864294
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluating the expression level of Survivin gene in different groups of B-cell acute lymphoblastic leukemia patients of Iran.
    Mohammadi M; Amirmahani F; Goharrizi KJ; Pakzad R; Dolat H
    Mol Biol Rep; 2019 Jun; 46(3):2679-2684. PubMed ID: 31037549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MiR-7 Functions as a Tumor Suppressor by Targeting the Oncogenes TAL1 in T-Cell Acute Lymphoblastic Leukemia.
    Sun H; Zhang Z; Luo W; Liu J; Lou Y; Xia S
    Technol Cancer Res Treat; 2020; 19():1533033820934130. PubMed ID: 32633635
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.